The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by ...

Recent developments in the health sector include Pfizer appointing Patrizia Cavazzoni as Chief Medical Officer and Amgen ...

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...

This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The ...

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024. Follow the ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required ...

Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...

It is also partnering with China-based Laekna to develop a similar drug. Regeneron is testing its drug, trevogrumab, along ...

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...